Malmström P U, Larsson A, Johansson S
Department of Urology, University of Uppsala, Sweden.
Br J Urol. 1993 Sep;72(3):307-10. doi: 10.1111/j.1464-410x.1993.tb00723.x.
The levels of fibronectin in urine from 106 patients with urinary bladder cancer, from 13 patients with benign urological disease and from 24 healthy control individuals were determined by an enzyme-linked immunosorbent assay (ELISA). The fibronectin levels in urine from patients with bladder cancer were higher than in patients with benign urothelial disease and in healthy controls. In 9 patients with bladder cancer, sampling was done both pre- and post-operatively. In these cases the fibronectin levels after operation were significantly lower than they had been before. Among 14 patients treated with BCG intravesically for superficial bladder tumours, those with complete remission of disease had less urinary fibronectin than those who did not respond to treatment. The data suggest that urinary fibronectin may be a useful marker for detecting urinary bladder cancer and for selecting patients for BCG treatment.
采用酶联免疫吸附测定法（ELISA）测定了106例膀胱癌患者、13例良性泌尿系统疾病患者及24名健康对照者尿液中的纤连蛋白水平。膀胱癌患者尿液中的纤连蛋白水平高于良性尿路上皮疾病患者及健康对照者。9例膀胱癌患者在术前和术后均进行了采样。在这些病例中，术后纤连蛋白水平明显低于术前。在14例接受卡介苗膀胱灌注治疗浅表膀胱肿瘤的患者中，疾病完全缓解者尿液中的纤连蛋白比治疗无反应者少。数据表明，尿液纤连蛋白可能是检测膀胱癌及选择卡介苗治疗患者的有用标志物。
